EEG changes, disturbed temperature regulation and seizures have also been reported. Pericyazine is generally well tolerated by epileptics maintained on anticonvulsive therapy. However, epileptic attacks have been reported and it has not been established that pericyazine effectively controls arousal or affective tension in these patients. Agranulocytosis and other blood dyscrasias are among the more serious adverse reactions to phenothiazines. They may occur suddenly or follow a fall in blood count, usually during the first 2 or 3 months of treatment.
Cholestatic jaundice occurs uncommonly.
Skin reactions, photosensitivity, asthma, laryngeal edema, angioneurotic edema, hyperpyrexia and other allergic reactions may also occur. Abnormal pigmentation, including corneal and lens deposits have been observed, usually when high doses of phenothiazines are given for prolonged periods. Voracious appetite and weight gain have been reported in some patients on pericyazine therapy. In some unexpected deaths, myocardial lesions have been observed. Several patients have shown sudden exacerbations of psychotic behavior patterns shortly before death.